Blueprint Medicines Corp (NAS:BPMC)
$ 102.81 0.42 (0.41%) Market Cap: 6.44 Bil Enterprise Value: 6.09 Bil PE Ratio: 0 PB Ratio: 20.73 GF Score: 72/100

Blueprint Medicines Corp VOYAGER Corporate Call Transcript

Apr 28, 2020 / 12:00PM GMT
Release Date Price: $58.63 (-17.31%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines Conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Mr. Jim Baker, Vice President of Corporate Affairs with -- of Blue Medicine -- Blueprint Medicine. Please go ahead, sir.

Julian Charles Baker

Thank you, operator. Good morning, everyone, and thank you for joining us today to review the top line results from VOYAGER, our Phase III clinical trial evaluating avapritinib in third-line GIST, which we reported earlier this morning. You can access the press release for the VOYAGER data as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.

With me today are -- with prepared remarks are Jeff Albers, our Chief Executive Officer; and Dr. Andy Boral, our Chief Medical Officer.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot